Answers are grounded in this paper and cite their sources.
Qualitative study reveals patient preferences for treatment options in non-muscle invasive bladder cancer, indicating the importance of considering trade-offs in future research.
This is the first study, to our knowledge, that provides qualitative evidence regarding patients' preference for potential future treatment options for HR-NMIBC. Findings will inform the final selection and framing of attributes and levels to be included in an upcoming benefit-risk preference study. Future research is warranted to quantify any trade-offs that patients with HR-NMIBC are willing to make regarding administration, benefit, and risk attributes.
No takes yet. Share an insight, caveat, or question.
Mason et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: